Sign in
4

Changes in Ownership

Dyne Therapeutics, Inc. Filed Acc 0001915598-26-000002

Chief Commercial Officer sold 145 shares at $18.33 ($2,658)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Friedl-Naderer Johanna Chief Commercial Officer 2026-06-16 Sale 10b5-1 −145 $18.33 $2,658 154,208 D: show line 1 in the form
Open-market sales · 145 sh · avg $18.33 · $2,658
Loading xslF345X06/ownership.xml…